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Background and Purpose—The modified Rankin Scale (mRS) at 3 months is the most commonly used primary outcome 
measure in stroke treatment trials, but it lacks specificity and requires long-term follow-up interviews, which consume 
time and resources. An alternative may be the National Institutes of Health Stroke Scale (NIHSS), early after stroke. Our 
aim was to evaluate whether the NIHSS assessed within 1 week after treatment could serve as a primary outcome measure 
for trials of acute treatment for ischemic stroke.
Methods—We used data from 2 randomized controlled trials of endovascular treatment for ischemic stroke: the positive 
MR CLEAN (Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the 
Netherlands; N=500) and the neutral IMS (Interventional Management of Stroke) III trial (N=656). We used a causal 
mediation model, with linear and ordinal logistic regression adjusted for confounders, to evaluate the NIHSS 24 
hours and 5 to 7 days after endovascular treatment as primary outcome measures (instead of the mRS at 3 months) 
in both trials. Patients who had died before the NIHSS was assessed received the maximum score of 42. NIHSS+1 
was then log10-transformed.
Results—In both trials, there was a significant correlation between the NIHSS at 24 hours and 5 to 7 days and the mRS. 
In MR CLEAN, we found a significant effect of endovascular treatment on the mRS and on the NIHSS at 24 hours 
and 5 to 7 days. After adjustment for NIHSS at 24 hours and 5 to 7 days, the effect of endovascular treatment on the 
mRS decreased from common odds ratio 1.68 (95% CI, 1.22–2.32) to respectively 1.36 (95% CI, 0.97–1.91) and 1.24 
(95% CI, 0.87–1.79), indicating that treatment effect on the mRS is in large part mediated by the NIHSS. In the IMS 
III trial there was no treatment effect on the NIHSS at 24 hours and 5 to 7 days, corresponding with the absence of a 
treatment effect on the mRS.
Conclusions—The NIHSS within 1 week satisfies the requirements for a surrogate end point and may be used as a primary 
outcome measure in trials of acute treatment for ischemic stroke, particularly in phase II(b) trials. This could reduce 
stroke-outcome assessment to its essentials (ie, neurological deficit), and reduce trial duration and costs. Whether and 
under which conditions it could be used in phase III trials requires a debate in the field with all parties.
Clinical Trial Registration—URL: http://www.isrctn.com. Unique identifier: ISRCTN10888758; https://www.clinicaltrials.
gov. Unique identifier: NCT00359424.   (Stroke. 2020;51:282-290. DOI: 10.1161/STROKEAHA.119.026791.)
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Acute treatment for ischemic stroke has been rapidly evolving over the past 5 years, resulting in a drastic im-
provement of functional outcome after ischemic stroke in 
selected patients. However, a considerable number of patients 
do not recover to functional independence after acute treat-
ment or are still not eligible for acute treatment.1–3 To im-
prove outcome and expand patient selection, new treatments 
or modifications to existing treatment modalities are continu-
ously being tested in novel (randomized) clinical trials. One of 
the most important considerations in the design of a valid and 
useful clinical trial is the selection of an appropriate primary 
outcome measure.4
The most commonly used primary outcome measure in (is-
chemic) stroke treatment trials is the modified Rankin Scale 
(mRS). This 7-point ordinal scale describes the degree of global 
disability or dependence in daily life after stroke, that is, func-
tional outcome.5 It is known for its simplicity and its ease of 
interpretation.6,7 However, the mRS has important practical lim-
itations. Because the mRS measures functional outcome and 
has a floor effect in the acute setting (ie, patients will receive 
mRS scores of 4 or 5 because they are often bed-bound during 
hospital admission), it should ideally be assessed after patients 
have had the chance to resume their daily activities; typically 
after 3 months.7,8 This long time span between treatment and 
outcome assessment may require intensive efforts to track down 
patients leading to increased trial duration and costs. Another 
undesirable result of this long time span is the risk of loss to fol-
low-up. When investigators are reluctant to enroll patients who 
are at high risk for loss to follow-up, for example, because of 
socioeconomic factors or visitors from abroad, this could also 
lead to slower patient enrollment and selection bias.
Because of the increasing interest in—and the need for—
rapid improvements in the acute treatment for ischemic stroke, 
efficient and cost-effective testing of new treatments is essen-
tial, especially for phase II(b) clinical trials, which are trials 
that are conducted to assess the efficacy of new treatments. 
Thus, early (surrogate) outcome measures are preferable for 
this purpose.
An alternative that may obviate the practical limitations 
of the mRS—the National Institutes of Health Stroke Scale 
(NIHSS)—is frequently used as an early secondary outcome 
measure in stroke trials. It is usually assessed 24 hours or 5 
to 7 days after the treatment. It measures neurological deficit 
rather than functional outcome. NIHSS scores range from 0 
to 42, with higher scores indicating more severe neurological 
deficit.9 The NIHSS has a high intraobserver and interobserver 
reliability after only a few hours of training, is easy and quick 
to assess, and is a valid measure of stroke severity.6,7,9 It reflects 
cerebral dysfunction by assessing several clinical items and is 
responsive to meaningful clinical change.6,9 Importantly, early 
NIHSS scores have a strong prognostic value for long-term 
functional outcome after stroke.10–12 However, the strong cor-
relation between NIHSS and mRS scores does not ensure that 
the NIHSS is a valid surrogate end point (ie, able to replace 
the mRS as a measure of treatment effect). A surrogate end 
point should lie in the causal pathway between the interven-
tion and the true end point.13
We used data from a positive and a neutral randomized 
controlled trial (RCT) of endovascular treatment (EVT) for 
ischemic stroke to evaluate whether the NIHSS within the 
first week after treatment could serve as a primary outcome 
measure for trials of acute treatment for ischemic stroke.
Methods
Data: MR CLEAN and IMS III Trial
Data were obtained from MR CLEAN (Multicenter Randomized 
Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke 
in the Netherlands)14 and the IMS (Interventional Management 
of Stroke) III trial.15 Anonymized trial data and methods that sup-
port our study findings are available for MR CLEAN upon reason-
able request to mrclean@erasmusmc.nl and via the public dataset 
through National Institutes of Health for the IMS III trial (https://
www.ninds.nih.gov/Current-Research/Research-Funded-NINDS/
Clinical-Research/Archived-Clinical-Research-Datasets).
MR CLEAN was a phase III, multicenter, open-label RCT that 
evaluated the efficacy and safety of EVT plus usual care (interven-
tion) compared with usual care alone (control) in patients with acute 
ischemic stroke. MR CLEAN enrolled 500 patients from 16 interven-
tion centers in the Netherlands between December 2010 and March 
2014. Enrolled patients were aged ≥18 years, had an ischemic stroke 
due to an intracranial large vessel occlusion in the anterior circulation 
with an NIHSS score of ≥2, and were able to undergo EVT within 
6 hours after symptom onset. The central medical ethics committee 
and research board of each participating center approved this study. 
All patients or their legal representatives provided written informed 
consent before randomization.
The IMS III trial was a phase III, multicenter, open-label RCT, 
evaluating whether EVT combined with intravenous thrombolysis 
(IVT) with recombinant tissue-type plasminogen activator in a dose 
of 0.6 mg/kg (intervention) within 3 hours of symptom onset was su-
perior to IVT alone (control). The IMS III trial enrolled 656 patients 
from 58 international centers between August 2006 and April 2012, 
aged 18 to 80 years with a moderate-to-severe ischemic stroke 
(NIHSS ≥10) before initiation of IVT. The study was approved by 
the ethics committee and research board of each participating center. 
Written informed consent was obtained from patients or their legal 
representative before enrollment in the study.
Causal Mediation Model
The causal pathway between the intervention (ie, treatment) and the 
true end point can be assessed with the Prentice criteria for surrogate 
end points,16 similar to the mediation model described by Baron and 
Kenny.17 Statistical validation of surrogate end points requires at least 
4 conditions to be satisfied (Figure):
1. There is a significant treatment effect on the true end point 
(pathway c);
2. There is a significant treatment effect on the surrogate end point 
(pathway a);
3. There is a significant correlation between the surrogate end 
point and the true end point while controlling for treatment 
(pathway b);
4. The surrogate end point mediates the effect of treatment on the 
true end point, that is, the significant treatment effect on the 
true end point becomes not statistically significant or should be 
reduced (ie, partial mediation) after adjusting for the surrogate 
end point (pathway c′).16,18
In the current analysis, the treatment was EVT. The ordinal mRS 
at 3 months was considered the true end point. In both trials, the mRS 
was assessed by independent assessors blinded to treatment alloca-
tion. The NIHSS at 24 hours and at 5 to 7 days (or at discharge if 
earlier) after EVT were considered the potential surrogate end points, 
also called the mediating variables. In both trials, NIHSS scores were 
assessed by the treating physician.
This traditional approach of mediation ignores the issue of con-
founding, which may also occur in RCTs. As a result of random-
ization, pathway a and pathway c could be assumed to be free of 
confounding. However, pathway b may contain (known and unknown) 
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confounders because both the surrogate end points and true end point 
are outcomes of randomization.18 Therefore, we adjusted for known 
confounders in pathway b and c′ (Figure).
The causal mediation model was applied to a trial with a positive 
treatment effect (MR CLEAN) and to a neutral trial (IMS III) to eval-
uate whether consistent relationships between pathway a and c were 
observed across the 2 trials.
Statistical Analyses
We compared baseline characteristics of patients in the interven-
tion group versus the control group for both trials using descriptive 
statistics. Pathway a and c were tested with univariable linear and 
ordinal logistic regression, respectively. All pathways were tested 
with multivariable linear (pathway a) and ordinal logistic regres-
sion (pathway b, c, c′). Patients who had died before the time point 
of NIHSS assessment was reached, received the maximum NIHSS 
score of 42. NIHSS scores at 24 hours and 5 to 7 days were then 
log10-transformed to better meet the assumption of normally distrib-
uted residuals in linear regression, after adding 1 point to all NIHSS 
scores, so that the log10-transformed NIHSS score of 0 would re-
main 0. The mRS did not require transformation, as it was analyzed 
with ordinal logistic regression.
Pathway b was also tested with univariable logistic regression 
with functional independence (ie, mRS, 0–2) as the true end point, 
to calculate the sensitivity and specificity of the NIHSS at 24 hours 
and 5 to 7 days for mRS 0 to 2 by performing Receiver Operating 
Characteristic-curve analyses. Pathway c and c′ are presented as 
(adjusted) common odds ratios ([a]cOR) with 95% CI, which are 
the pooled estimates of the effect on each cutoff point on the mRS. 
Pathway a was estimated as an (adjusted regression coefficient beta; 
aβ) and is expressed as percentage increase or decrease of the NIHSS 
score in the intervention compared with the control group, with 95% 
CI. Pathway b is presented as the acOR for every 10% increase in the 
NIHSS score, with 95% CI.
Regression analyses of pathway a and c were adjusted for age, 
baseline NIHSS, collateral score on computed tomography angi-
ography, and onset-to-randomization time. Regression analysis of 
pathway b and c′ were adjusted for age, sex, baseline NIHSS, pre-
stroke mRS, diabetes mellitus, hypertension, ischemic stroke, atrial 
fibrillation, internal carotid artery terminus occlusion, collateral score 
on computed tomography angiography, IVT (in MR CLEAN only), 
and onset-to-randomization time.
Missing data of the confounders, the true end point, and the 
surrogate end points were replaced per trial by multiple imputa-
tion with regression based on relevant covariates and outcomes. 
We performed a sensitivity analysis of the causal mediation model, 
in which NIHSS scores of patients who had died before the time 
point of NIHSS assessment was reached were also imputed with 
multiple imputation with regression. Statistical analyses were per-
formed with Stata/SE software version 15.1 (StataCorp, College 
Station, TX).
Results
All 500 patients in MR CLEAN and all 656 patients in the IMS 
III trial were included in this study. Baseline characteristics 
were similar in the intervention and control group for both trials 
(Table 1). Median age was 66 in MR CLEAN and 69 in the IMS 
III trial, and respectively, 58% and 52% of the patients were men.
In MR CLEAN, 12 patients who had died within 24 hours 
and 57 patients who had died within 5 to 7 days were assigned 
the maximum NIHSS score of 42. After this, missing NIHSS 
scores (8 at 24 hours and 18 at 5 to 7 days) were replaced by 
multiple imputation with regression. In the IMS III trial, the 
maximum NIHSS score of 42 was assigned to the 15 patients 
who died within 24 hours and 68 patients who died within 5 to 7 
days. Missing NIHSS scores at 24 hours (n=31) and 5 to 7 days 
(n=29) were replaced by multiple imputation with regression.
Mediation Analysis
In present analysis of MR CLEAN, EVT was associated 
with a significant improvement of functional outcome, with 
an acOR of 1.68 (95% CI, 1.22–2.32; pathway c; Table 2). 
Patients treated with EVT had lower NIHSS scores than 
patients in the control group at 24 hours (aβ, −17% [95% CI, 
−26 to −6.4]) and at 5 to 7 days (aβ, −24% [95% CI, −36 to 
−11]; pathway a). This means that—for example—a patient in 
the control group with an NIHSS score of 15 at 24 hours or 5 
to 7 days would have had an NIHSS score of 12 (15−15×0.17) 
at 24 hours or 11 (15−15×0.25) at 5 to 7 days after EVT. The 
NIHSS at 24 hours was correlated with the mRS (acOR, 0.79 
[95% CI, 0.77–0.82]), as was the NIHSS at 5 to 7 days (acOR, 
0.77 [95% CI, 0.75–0.80]; pathway b). The sensitivity and 
specificity of the NIHSS at 24 hours for mRS 0 to 2 was 85% 
at the optimal cutoff point (area under the Receiver Operating 
Characteristic-curve=0.91). For the NIHSS at 5 to 7 days, this 
was 88% (area under the Receiver Operating Characteristic 
curve=0.94; Figure I in the online-only Data Supplement). 
The effect of EVT on the mRS was not statistically significant 
after adjustment for NIHSS at 24 hours (acOR, 1.36 [95% 
CI, 0.97–1.91]) nor after adjustment for NIHSS at 5 to 7 days 
(acOR, 1.24 [95% CI, 0.87–1.79]; pathway c′).
In the IMS III trial, we did not find a significant treat-
ment effect of EVT on the ordinal mRS (acOR, 1.30 [95% 
CI, 0.97–1.75]; pathway c), nor on the NIHSS at 24 hours (aβ 
Figure. Applied causal mediation model. ICA-T 
indicates internal carotid artery terminus; IVT, 
intravenous thrombolysis; mRS, modified 
Rankin Scale; NIHSS, National Institutes of 
Health Stroke Scale. *In MR CLEAN (Multicenter 
Randomized Clinical Trial of Endovascular 
Treatment for Acute Ischemic Stroke in the 
Netherlands) only.
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−4.0% [95% CI, −17 to 11]) or 5 to 7 days (aβ −10% [95% 
CI, −25 to 7.4]; pathway a). The NIHSS at 24 hours and at 5 to 
7 days were correlated with the mRS (both acOR, 0.79 [95% 
CI, 0.77–0.81]; pathway b). The sensitivities and specificities 
of the NIHSS at 24 hours and 5 to 7 days for mRS 0 to 2 were 
similar to those of the MR CLEAN (Figure I in the online-only 
Data Supplement). Because no significant treatment effect was 
found on pathway c, pathway c′ was not tested in these data.
Results of the sensitivity analysis, in which we imputed 
NIHSS scores for patients who had died instead of assigning 
them 42 points, were comparable to those of the main analysis 
(Table I in the online-only Data Supplement). Distributions 
of the NIHSS and log10-transformed NIHSS+1 in the main 
analysis and sensitivity analysis are given in Figures II through 
V in the online-only Data Supplement.
For pathways a and c of both trials, unadjusted results are 
provided in Table II in the online-only Data Supplement.
Discussion
We used a causal mediation model to assess the early NIHSS 
as a surrogate end point for the mRS at 3 months in a positive 
and a neutral RCT of EVT for ischemic stroke. We found the 
NIHSS to be a valid outcome measure for treatment effect that 
mediates the effect of EVT on the mRS.
Although this is the first study to formally evaluate the 
early NIHSS as a surrogate end point with a causal mediation 
Table 1. Baseline Characteristics of Patients in MR CLEAN and the IMS III Trial According to Treatment Allocation
MR CLEAN IMS III Trial
Intervention (N=233) Control (N=267) Intervention (N=434) Control (N=222)
Age in years, median (IQR) 66 (55–76) 66 (56–76) 69 (58–76) 68 (57–77)
Men, n/N (%) 135/233 (58%) 157/267 (59%) 218/434 (50%) 122/222 (55%)
NIHSS, median (IQR)* 17 (14–21) 18 (14–22) 17 (13–20) 16 (13–21)
Systolic blood pressure in mm Hg, mean (SD)† 146 (26) 145 (24) 150 (28) 152 (29)
Intravenous thrombolysis, n/N (%) 203/233 (87%) 242/267 (91%) 434/434 (100%) 222/222 (100%)
Time from symptom onset to randomization in 
minutes, median (IQR)‡
204 (152–251) 196 (149–266) 144 (120–170) 140 (115–165)
Medical history
  Atrial fibrillation, n/N (%) 66/233 (28%) 69/267 (26%) 135/424 (32%) 62/219 (28%)
  Diabetes mellitus, n/N (%) 34/233 (15%) 34/267 (13%) 94/432 (22%) 54/220 (25%)
  Hypertension, n/N (%) 98/233 (42%) 129/267 (48%) 319/432 (74%) 171/220 (78%)
  Previous ischemic stroke, n/N (%) 29/233 (12%) 25/267 (9.4%) 58/431 (13%) 32/222 (14%)
Prestroke modified Rankin Scale, n/N (%)
  0 190/233 (82%) 214/267 (80%) 379/434 (87%) 197/222 (89%)
  1 21/233 (9.0%) 29/267 (11%) 35/434 (8.1%) 21/222 (9.5%)
  2 12/233 (5.2%) 13/267 (4.9%) 19/434 (4.4%) 4/222 (1.8%)
  ≥3 10/233 (4.3%) 11/267 (4.1%) 1/434 (0.2%) 0/222 (0%)
Imaging
  ICA-T occlusion location, n/N (%) 59/233 (25%) 75/267 (28%) 39/410 (9.5%) 19/206 (9.2%)
  ASPECTS on NCCT, median (IQR)§ 9 (7–10) 9 (8–10) 8 (6–10) 8 (6–10)
Collateral score on CT angiography, n/N (%)‖
  0 9/231 (3.9%) 17/262 (6.5%) 12/134 (9.0%) 2/65 (3.1%)
  1 72/231 (31%) 64/262 (24%) 26/134 (19%) 15/65 (23%)
  2 88/231 (38%) 110/262 (42%) 33/134 (25%) 21/65 (32%)
  3 62/231 (27%) 71/262 (27%) 63/134 (47%) 27/65 (42%)
ASPECTS indicates Alberta Stroke Program Early CT Score; CT, computed tomography; ICA-T, internal carotid artery terminus; IMS III, 
Interventional Management of Stroke III; IQR, interquartile range presented as the 25th and 75th percentile; MR CLEAN, Multicenter Randomized 
Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands; NCCT, noncontrast computed tomography; and NIHSS, 
National Institutes of Health Stroke Scale.
*Missing data in the IMS III trial: 2.
†Missing data in the IMS III trial: 8.
‡Missing data in MR CLEAN: 2.
§The ASPECTS ranges from 0 to 10, with higher scores indicating fewer early ischemic changes; missing data in MR CLEAN: 4; missing data 
in the IMS III trial: 7.
‖The collateral score is a scale from 0 to 3, with 0 representing absent collateral flow and 3 good collateral flow.
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model, our results are supported by previous findings. In a 
meta-analysis of 5 RCTs, the strong beneficial effect of EVT 
was shown on both the NIHSS at 24 hours (pathway a) and 
the mRS at 3 months (pathway c).1 In 3 other RCTs of EVT 
that assessed the mRS at 3 months and the NIHSS at 24 hours 
or 7 days, treatment effect of EVT was similar on both out-
come measures (ie, either both positive19 or both neutral20,21). 
Moreover, the predictive value of the NIHSS within 1 week 
after ischemic stroke for the mRS at 3 months (pathway b) 
has been demonstrated before.10–12 These previous findings 
provide reliable evidence of the validity of the NIHSS as a 
surrogate end point for functional outcome.22 The high sen-
sitivities, specificities, and corresponding areas under the 
Receiver Operating Characteristic-curves of the NIHSS pre-
dicting functional independence at 3 months in our study sub-
stantiate this as well.
Regarding the optimal timing of the NIHSS assessment, 
it has previously been pointed out that the 7-day relative neu-
rological improvement on NIHSS can predict 90-day func-
tional outcome after EVT better than the 24-hour relative 
neurological improvement.23 The NIHSS at 24 hours might 
miss important evolution of ischemic damage or early com-
plications. Although the NIHSS at 5 to 7 days mediated the 
effect of EVT on the mRS most, the importance of the NIHSS 
at 24 hours should not be underestimated as it is less inflicted 
by loss of patients because of early death, which was also vis-
ible by the distributions of the NIHSS scores. NIHSS at 24 
hours may also be more useful in practice, simply because it 
is assessed early after trial inclusion.
The selection of an appropriate primary outcome measure 
is a critical and challenging step in the design of a clinical 
trial that concerns investigators, regulatory authorities, pro-
fessional organizations writing guidelines, and trial sponsors. 
It depends on the disease and the expected mechanism and 
effect of the treatment under study. We studied the NIHSS as 
an outcome measure in 2 RCTs of EVT for ischemic stroke. 
Validation of surrogate end points is treatment specific. 
However, we think that our findings can be generalized to 
ischemic stroke trials investigating an acute treatments with 
an early expected effect, that is, to treatments in which the 
NIHSS lies on the causal pathway between the treatment 
and the mRS.13,16 This is supported by the fact that in all pre-
vious RCTs of IVT or intraarterial (recombinant) tissue-type 
plasminogen activator that assessed both the mRS at 3 months 
and NIHSS at 24 hours, treatment effect was similar on both 
outcome measures (ie, either both positive or both neutral).24–28
A primary outcome measure should ideally be simple; 
easy and quick to assess; reliable; valid; responsive to mean-
ingful change; evaluating impairments, disabilities, handicaps, 
or quality of life; and be free of bias.29 Although the mRS is 
widely considered to be the standard primary outcome measure 
in trials of acute treatment for ischemic stroke, it does not meet 
all these criteria. Apart from the practical limitations that are 
caused by the long time span between treatment and outcome 
assessment, the mRS also has other limitations. First, the mRS 
lacks specificity because it includes all kinds of disability—
including disability not related to the stroke or treatment. This 
might be the case for adverse events that occur between day 7 
and day 90 after stroke onset or for disability that existed before 
the stroke, which is influenced by patient comorbidity, socioec-
onomic factors, and cognitive abilities.3 Second, the use of the 
mRS may influence trial results due to the moderate interob-
server reliability.30 Third, although a single-point change on the 
mRS can often be deemed clinically relevant, compared with 
other stroke-outcome measures with more items, such as the 
NIHSS, the mRS may be less responsive to change because of 
its limited number of categories.6,7 Over time, several alterna-
tive early primary or surrogate outcome measures have been 
proposed, including the NIHSS at 24 hours or 5 to 7 days, mRS 
at 1 week, follow-up infarct volume at 1 week on computed 
tomography or magnetic resonance imaging, and reperfusion 
directly after treatment on digital subtraction angiography.3,31–34 
Follow-up infarct volume has been formally evaluated as a me-
diator of the mRS but did not meet the expectations of an early 
surrogate end point.31,33
Next to the advantages of the early NIHSS (ie, assessed 
during hospital stay, reliable, easy and quick to assess, valid 
measure of stroke severity, responsive to meaningful change),6,7,9 
using the NIHSS as a primary outcome measure in (random-
ized) clinical trials has some practical disadvantages as well. 
First, the NIHSS does not include death. Excluding deceased 
patients would bias treatment effect estimates substantially 
when the mortality is not equally distributed between treatment 
arms, which is likely when a treatment is effective. Therefore, 
we assigned deceased patients the maximum score of 42 and 
performed a sensitivity analyses in which we imputed NIHSS 
Table 2. Application of the Causal Mediation Model in MR CLEAN and the IMS III Trial*
Pathway a Effect of EVT on NIHSS (aβ)
Pathway b Correlation Between NIHSS 
and mRS Adjusted for EVT (acOR†)
Pathway c Effect 
of EVT on mRS 
(acOR)
Pathway c′ Effect of EVT on mRS 
Adjusted for NIHSS (acOR)
NIHSS 24 h NIHSS 5–7 days NIHSS 24 h NIHSS 5–7 days NIHSS 24 h NIHSS 5–7 days
MR CLEAN −17% (−26 to −6.4)‡ −24% (−36 to −11) 0.79 (0.77 to 0.82) 0.77 (0.75 to 0.80) 1.68 (1.22 to 2.32) 1.36 (0.97 to 1.91) 1.24 (0.87 to 1.79)
IMS III trial −4.0% (−17 to 11) −10% (−25 to 7.4) 0.79 (0.77 to 0.81) 0.79 (0.77 to 0.81) 1.30 (0.97 to 1.75) N/A N/A
aβ indicates adjusted regression coefficient beta; acOR, adjusted common odds ratio; EVT, endovascular treatment; IMS III, Interventional Management of Stroke 
III; MR CLEAN, Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands; mRS, modified Rankin Scale; N/A, not 
applicable; and NIHSS, National Institutes of Health Stroke Scale.
*All acORs and aβs are reported with their 95% CIs. All pathways are adjusted for age, baseline NIHSS, collateral score, time from symptom onset to randomization. 
Pathway b and c′ are additionally adjusted for sex, prestroke mRS, diabetes mellitus, hypertension, ischemic stroke, atrial fibrillation, ICA-T occlusion, IVT (in MR CLEAN 
only). Pathway c′ was not tested in the IMS III trial since no significant treatment effect was found on pathway c.
†Expressed as an acOR for every 10% increase in the NIHSS.
‡Interpretation of aβ: a patient with an NIHSS score of 15 at 24 h after treatment with usual care alone, would have an NIHSS score of 12 at 24 h when treated with 
EVT + usual care (15−15×0.17).
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scores of deceased patients. Although imputing deceased 
patients might statistically lead to better distributions of the 
(log10-transformed) NIHSS at 5 to 7 days, results of the medi-
ation model were comparable, and intuitively stroke physicians 
and investigators may not consider it appropriate to impute out-
comes of deceased patients. Including deceased patients in the 
NIHSS score, regardless of the approach that was used, leads 
to a non-normal distribution of the NIHSS, requiring a trans-
formation. Whether our approach of the log10(NIHSS+1)-
transformation is best for analyzing the NIHSS as a measure 
of treatment effect, while also taking into consideration how 
to easily interpret the outcome, needs further evaluation. The 
interpretation of the log10-transformed NIHSS+1 may sound 
challenging but comes down to expressing treatment effect as 
percentage increase or decrease of NIHSS scores in the inter-
vention versus control group. A specific limitation of our study 
was that NIHSS scores were assessed in a nonblinded manner, 
which may have led to overestimation of the treatment effect 
on the NIHSS in MR CLEAN. Nevertheless, consistency in 
our results—specifically that no treatment effect was observed 
on the NIHSS in the IMS III trial—suggests that nonblinded 
assessment of the NIHSS did not substantially overestimate the 
observed treatment effect on the NIHSS in MR CLEAN. If the 
NIHSS is used as a surrogate end point in trials, blinded NIHSS 
scores could, for example, be obtained by video assessment.
For selection of the most appropriate primary outcome 
measure, it is also important to take the phase of the trial into 
consideration. The early NIHSS could be a very useful pri-
mary outcome measure in phase II(b) trials testing the effect 
of new therapeutic agents or interventions for ischemic stroke, 
as was also proposed in two previous simulation studies using 
RCT data of IVT.32,34
 Because of its assessment during hos-
pital stay, using the NIHSS as a primary outcome measure 
may not only lead to reduced trial duration and costs, but as 
the NIHSS is a more direct measure of the effect of EVT (ie, 
restoring blood flow to ischemic brain tissue), it could be val-
uable in phase II(b) trials for a first assessment of the effect of 
new therapeutic agents or interventions, and for guiding deci-
sions about whether this new treatment should be evaluated in 
a (larger) phase III trial.
Whether the NIHSS may also be useful in (confirmatory) 
phase III trials is a challenging question. In our study, we have 
proven the NIHSS to be a valid surrogate end point for the 
mRS. One might argue that based on our findings and on pre-
vious research, there is plenty of evidence that it could be used 
as a surrogate end point in phase III trials. This merits con-
sideration, especially for confirmatory phase III trials, which 
test modifications of treatments that have already been proven 
to be effective and safe, such as the comparison of various 
(new) types of mechanical thrombectomy devices or fibrino-
lyic agents. In general, relying too quickly on surrogate end 
points as the primary source of efficacy information of new 
treatments may result in limited insights regarding efficacy, 
as well as less reliable estimates of safety and side effects.22
A more fundamental question in this debate is whether the 
early NIHSS is able to measure what we want to achieve with 
a specific treatment. Fleming et al22 stated that when selecting 
the primary end point in phase III trials, the effects on such 
an end point should provide reliable evidence about whether 
a new treatment provides clinically meaningful benefit (ie, the 
primary outcome measure should be [1] “a clinical event rele-
vant to the patient,” or [2] an “end point that measures directly 
how a patient feels, functions or survives”). There is increas-
ing interest in more patient-oriented outcomes such as Patient-
Reported Outcome Measures, as it is believed that these matter 
most to patients. In stroke, the utility-weighted mRS was advo-
cated as a more patient-oriented outcome.35 In contrast, the 
NIHSS provides limited information on how a stroke affects 
patients in their daily lives (eg, on a functional and/or emo-
tional level). An NIHSS score of 1 is generally considered to 
represent an excellent outcome, but even a partial hemianopia 
or moderate aphasia could have severe consequences for the 
patient’s quality of life.6 However, although the mRS better 
represents the impact of a treatment on a patient’s daily life, the 
NIHSS provides a more direct measure of treatment effect and 
is more responsive to change than the mRS with its limited cat-
egories. Therefore, clinically relevant effects of new treatments 
may be captured more easily with the NIHSS. Improvement on 
one of the neurological functions measured with NIHSS will 
be meaningful to most, if not all, patients. This could partic-
ularly be considered relevant in phase II(b) and confirmatory 
phase III trials. Taken together, the NIHSS and mRS do not 
measure the exact same thing, but based on the statement of 
Fleming et al,22 we can conclude that both the effects on the 
NIHSS and mRS could provide evidence whether a new treat-
ment provides clinically meaningful benefit.
Even aside from considerations such as whether we owe 
it to our patients to fully establish improvement of functional 
outcome in the long run, we have to consider that effects of 
new treatments may be influenced by delayed effects of com-
plications, such as pneumonia and deep venous thrombosis. 
Early outcome measures might miss that. Especially when 
effects in the weeks after start of the treatment are expected, 
the mRS may be the better choice.
All in all, selecting the most appropriate outcome measure 
for trials of acute treatment for ischemic stroke poses a major 
challenge for investigators, regulatory authorities, profes-
sional organizations writing guidelines, and trial sponsors, 
which also has important clinical implications for patients. 
Thus, before being able to recommend the use of the NIHSS 
in phase III trials, a debate, or maybe even a consensus agree-
ment, in the field with all parties is required.
Conclusions
The NIHSS within 1 week after EVT fulfills the requirements 
for a surrogate end point. It may be used as a primary outcome 
measure in phase II(b) trials of acute treatment for ischemic 
stroke. This could reduce stroke-outcome assessment to its 
essentials and also reduce trial duration and costs. A debate 
in the field is required to determine whether and under which 
conditions the NIHSS could be used as a primary outcome 
measure in (confirmatory) phase III trials.
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